Skip main navigation

EGFR and tumor cells

EGFR and tumor cells

Binding of EGFR to its cognate ligands leads to autophosphorylation of the receptor itself by the tyrosine kinase activity.

A variety of signal transduction pathways are subsequently activated, which are involved in regulating cellular proliferation, differentiation, and survival.

Although EGFR is also produced in normal cells, it is overexpressed in a variety of tumor cell lines and has been associated with poor prognosis and reduced survival rate.

Moreover, EGFR activation in tumor cells also plays a role in resistance to chemotherapy and radiation treatment.

Over the past two decades, much effort has been directed at developing anticancer agents which can interfere with EGFR activity.

Now, the most common pharmacologic approaches to EGFR inhibition have been achieved by the developments of monoclonal antibodies and small-molecule inhibitors.

This article is from the free online

Introduction to Translational Research: Connecting Scientists and Medical Doctors

Created by
FutureLearn - Learning For Life

Reach your personal and professional goals

Unlock access to hundreds of expert online courses and degrees from top universities and educators to gain accredited qualifications and professional CV-building certificates.

Join over 18 million learners to launch, switch or build upon your career, all at your own pace, across a wide range of topic areas.

Start Learning now